Recombinant Bovine PRA1 family protein 3 (ARL6IP5)

What is ARL6IP5 and what are its primary functions?

ARL6IP5, also known as PRA1 family protein 3, is a protein that contains a prenylated Rab acceptor motif involved in intracellular protein transport regulation. Its expression is affected by vitamin A, and it may be associated with the cytoskeleton. The protein plays significant roles in several cellular processes, including regulation of cell differentiation, inhibition of glutamate transporter EAAC1, and involvement in the endoplasmic reticulum (ER) stress response pathway. It also functions as a repair protein in oxidative stress-induced DNA single-strand breaks in fibroblasts through regulation of XRCC1 via the MAPK signal pathway .

What cellular pathways involve ARL6IP5?

ARL6IP5 participates in multiple cellular pathways that are crucial for neuronal function and cellular stress responses. Key pathways include:

ARL6IP5 is particularly important in these pathways through its interaction with glutamate transporters and its role in protein trafficking .

How is ARL6IP5 expression regulated at the cellular level?

ARL6IP5 expression is primarily regulated by vitamin A and its metabolite retinoic acid. Research has demonstrated that retinoic acid upregulates the expression of ARL6IP5, which subsequently leads to a specific reduction in EAAC1-mediated glutamate transport. This regulatory mechanism highlights the importance of ARL6IP5 in glutamatergic neurotransmission.

Additionally, ARL6IP5 expression is compensatorily upregulated in response to chronically activated unfolded protein response (UPR) in cellular stress conditions, such as in prion disease models. This upregulation serves as a protective mechanism against ER stress, suggesting ARL6IP5 plays a crucial role in cellular stress adaptation mechanisms .

What role does ARL6IP5 play in DNA repair mechanisms and cisplatin resistance?

ARL6IP5 functions as a critical regulator of DNA repair mechanisms, particularly in response to cisplatin treatment. Research has identified ARL6IP5 as a novel gene that suppresses cisplatin resistance by:

• Activating apoptotic pathways in response to DNA damage

• Inhibiting DNA repair through direct interaction with XRCC1 and PARP1

• Protecting XRCC1 from ubiquitination and degradation

• Regulating the MAPK signaling pathway involved in DNA repair

In ovarian cancer models, ARL6IP5 overexpression significantly reduces cisplatin resistance by interfering with these DNA repair mechanisms. Conversely, knockdown of ARL6IP5 enhances cisplatin resistance by allowing more efficient DNA repair through XRCC1 and PARP1 pathways. This mechanism suggests that ARL6IP5 expression levels could serve as a potential biomarker for predicting cisplatin treatment response in certain cancers .

How does ARL6IP5 regulate ER stress and reticulophagy, and what are the implications for neurodegenerative diseases?

ARL6IP5 functions as a novel ER stress regulator by inducing reticulophagy (selective autophagy of the ER) through several mechanisms:

• Overexpression of ARL6IP5 overcomes ER stress by reducing the expression of chronically activated UPR pathway proteins

• ARL6IP5 induces reticulophagy to reduce misfolded protein burden (notably PRNP/PrPSc in prion disease models)

• This process depends on Ca2+-mediated AMPK activation and can induce autophagy even in the presence of 3-MA (an autophagy inhibitor)

• ARL6IP5-induced reticulophagy involves direct interaction with the soluble reticulophagy receptor CALCOCO1 and lysosomal marker LAMP1

Knockdown of ARL6IP5 leads to inefficient autophagic flux and elevated misfolded protein burden, suggesting its critical role in protein quality control mechanisms. The ability of ARL6IP5 to regulate ER stress and protein misfolding makes it a potential therapeutic target for neurodegenerative diseases, particularly prion diseases, where protein misfolding is a central pathological feature .

What experimental approaches are most effective for studying ARL6IP5-mediated reticulophagy?

To effectively study ARL6IP5-mediated reticulophagy, researchers should consider a multi-faceted experimental approach:

• Genetic manipulation: Utilize overexpression and knockdown models of ARL6IP5 in relevant cell lines to establish cause-effect relationships.

• Autophagy flux assays: Monitor autophagosome formation and degradation using:

  • LC3-II conversion assays with and without lysosomal inhibitors

  • Tandem fluorescent-tagged LC3 (mRFP-GFP-LC3) to distinguish early autophagosomes from autolysosomes

  • Co-localization studies of ER markers with autophagy proteins

• ER stress monitoring: Assess UPR pathway activation through:

  • Western blot analysis of UPR proteins (BiP, PERK, IRE1α, ATF6)

  • XBP1 splicing assays

  • CHOP expression analysis

• Protein-protein interaction studies:

  • Co-immunoprecipitation of ARL6IP5 with CALCOCO1 and LAMP1

  • Proximity ligation assays to visualize interactions in situ

  • FRET/BRET analyses for dynamic interaction studies

• Calcium signaling assessment:

  • Live cell calcium imaging using fluorescent indicators

  • Measurement of calcium release from ER stores

  • Analysis of AMPK activation downstream of calcium signaling

• Functional outcomes measurement:

  • Assessment of misfolded protein clearance (e.g., PrPSc levels)

  • Cell viability and apoptosis assays

  • ER morphology analysis using fluorescence and electron microscopy

How does ARL6IP5 influence glutamate transport and what are the implications for neurological disorders?

ARL6IP5 exerts significant influence on glutamate transport through direct interaction with the glutamate transporter EAAC1 (also known as EAAT3 or SLC1A1). The molecular mechanisms and implications include:

• Direct inhibition: ARL6IP5 binds and inhibits EAAC1, reducing glutamate uptake capacity in neurons and glial cells.

• Retinoic acid-mediated regulation: Upregulation of ARL6IP5 by retinoic acid results in specific reduction of EAAC1-mediated glutamate transport, establishing a vitamin A-dependent regulatory mechanism.

• Subcellular trafficking effects: ARL6IP5 likely affects the membrane localization and recycling of EAAC1, thereby modulating its availability at the cell surface.

• Implication in excitotoxicity: By regulating glutamate clearance, ARL6IP5 may modulate excitotoxic neuronal damage in conditions like stroke, epilepsy, and neurodegenerative diseases.

• Potential role in psychiatric disorders: Given the importance of glutamatergic signaling in conditions like schizophrenia, OCD, and anxiety disorders (where EAAC1 has been implicated), ARL6IP5 may represent an unexplored contributor to these conditions .

The relationship between ARL6IP5 and glutamate transport suggests potential therapeutic applications in neurological disorders characterized by glutamatergic dysregulation, pending further investigation in appropriate disease models.

What are the optimal conditions for working with recombinant bovine ARL6IP5 protein?

When working with recombinant bovine ARL6IP5 protein, researchers should implement the following optimized conditions:

What experimental designs are most effective for studying ARL6IP5's role in DNA repair?

To effectively investigate ARL6IP5's role in DNA repair mechanisms, particularly in the context of cisplatin resistance, the following experimental design strategies are recommended:

• Cell line selection and manipulation:

  • Use paired cisplatin-sensitive and resistant cancer cell lines (e.g., A2780/A2780-CP for ovarian cancer)

  • Generate stable ARL6IP5 overexpression and knockdown models using lentiviral systems

  • Consider CRISPR/Cas9 for complete knockout studies when appropriate

• DNA damage induction and quantification:

  • Treat cells with cisplatin at IC50 concentrations determined for each cell line

  • Measure DNA damage through comet assay (alkaline conditions for single-strand breaks)

  • Quantify γ-H2AX foci formation through immunofluorescence microscopy

  • Assess platinum-DNA adduct formation using atomic absorption spectroscopy

• Repair pathway analysis:

  • Monitor DNA repair kinetics by measuring damage markers at different time points post-treatment

  • Specifically assess nucleotide excision repair (NER) pathway activity using host-cell reactivation assays

  • Examine homologous recombination efficiency with DR-GFP reporter assays

• Protein interaction studies:

  • Perform co-immunoprecipitation of ARL6IP5 with XRCC1 and PARP1

  • Conduct proximity ligation assays to visualize interactions in situ

  • Examine changes in XRCC1 ubiquitination status in the presence/absence of ARL6IP5

• Signaling pathway analysis:

  • Assess MAPK pathway activation through phosphorylation status of key components

  • Use pathway inhibitors to determine dependency of ARL6IP5 functions on specific signaling cascades

• Functional outcomes:

  • Measure cell survival and apoptosis following cisplatin treatment

  • Assess colony formation as an indicator of long-term survival

  • Conduct cell cycle analysis to determine checkpoint activation

• In vivo validation:

  • Establish xenograft models with ARL6IP5-modulated cells

  • Monitor tumor growth in response to cisplatin treatment

  • Analyze tumor samples for DNA repair markers and pathway activation

What are the most reliable techniques for studying ARL6IP5-mediated protein interactions?

Studying ARL6IP5-mediated protein interactions requires a comprehensive approach incorporating multiple complementary techniques:

• Co-immunoprecipitation (Co-IP):

  • Use either anti-ARL6IP5 antibodies or antibodies against suspected interaction partners

  • Include appropriate controls (IgG control, reverse Co-IP)

  • Enhance detection with crosslinking for transient interactions

  • Consider native Co-IP conditions to preserve physiological complexes

• Proximity-based methods:

  • Proximity Ligation Assay (PLA) for visualizing interactions in fixed cells with high sensitivity

  • BioID or TurboID for detecting proximal proteins in living cells

  • FRET/BRET for studying dynamic interactions and conformational changes

• Pull-down assays:

  • Use purified recombinant ARL6IP5 (GST or His-tagged) as bait

  • Perform with cell lysates to identify novel interacting partners

  • Test with purified candidates to confirm direct interactions

  • Include competition assays to assess binding specificity

• Yeast two-hybrid screening:

  • Use ARL6IP5 as bait to screen for novel interaction partners

  • Validate positive hits with reciprocal tests and other methods

  • Consider membrane yeast two-hybrid for membrane protein interactions

• Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI):

  • Determine binding kinetics and affinity constants

  • Assess the effects of mutations on interaction strength

  • Study the impact of post-translational modifications

• Mass spectrometry-based approaches:

  • Immunoprecipitation coupled with MS for identification of complexes

  • Crosslinking Mass Spectrometry (XL-MS) to map interaction interfaces

  • Hydrogen-Deuterium Exchange MS to study conformational changes upon binding

• Visualization techniques:

  • Fluorescence colocalization using confocal microscopy

  • Super-resolution microscopy for detailed spatial analysis

  • Live cell imaging with fluorescently-tagged proteins to track dynamic interactions

The combination of these techniques provides a robust framework for characterizing ARL6IP5 interactions with partners such as XRCC1, PARP1, CALCOCO1, and LAMP1, which are crucial for understanding its roles in DNA repair and reticulophagy .

What are the most promising therapeutic applications of ARL6IP5 research?

Based on current understanding of ARL6IP5 functions, several promising therapeutic applications warrant further investigation:

• Cancer therapy sensitization:

  • Development of small molecules that mimic ARL6IP5's inhibitory effect on DNA repair to enhance cisplatin sensitivity

  • Combination therapy approaches targeting both ARL6IP5 and DNA repair pathways

  • Biomarker development using ARL6IP5 expression levels to predict cisplatin response

• Neurodegenerative disease interventions:

  • Targeted upregulation of ARL6IP5 to enhance clearance of misfolded proteins in prion diseases

  • Modulation of ARL6IP5-dependent reticulophagy to reduce ER stress in protein misfolding disorders

  • Development of small molecule enhancers of ARL6IP5-CALCOCO1 interaction to boost selective autophagy

• Glutamatergic system modulation:

  • Fine-tuning of ARL6IP5-EAAC1 interactions to modify glutamate clearance in excitotoxicity-related conditions

  • Development of compounds that modulate ARL6IP5 binding to glutamate transporters

  • Targeted approaches for disorders involving glutamatergic dysfunction

• ER stress-related pathologies:

  • Leveraging ARL6IP5's role in ER stress regulation for metabolic disorders

  • Exploring applications in ischemia-reperfusion injury where ER stress is prominent

  • Developing cellular resilience enhancement strategies based on ARL6IP5 pathways

Future therapeutic development will require deeper understanding of tissue-specific functions and the development of targeted delivery systems for ARL6IP5-modulating compounds or gene therapies.